{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T19:06:01Z","timestamp":1762542361153,"version":"build-2065373602"},"reference-count":30,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Fundaci\u00f3n para el Estudio de la Hematologia y la Hemoterapia en Arag\u00f3n"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1016\/j.clml.2015.02.025","type":"journal-article","created":{"date-parts":[[2015,3,4]],"date-time":"2015-03-04T23:03:51Z","timestamp":1425510231000},"page":"464-471","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Patients Older Than 65 Years With Non-Hodgkin Lymphoma Are Suitable for Treatment With 90Yttrium-Ibritumumab Tiuxetan: A Single-Institution Experience"],"prefix":"10.1016","volume":"15","author":[{"given":"Marcio M.","family":"Andrade-Campos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anel E.","family":"Montes-Lim\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gloria","family":"Soro-Alcubierre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Lievano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"L\u00f3pez-G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Baringo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pilar","family":"Giraldo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2015.02.025_bib1","unstructured":"Leukemia and Lymphoma Society. Facts 2012. Statistics Review. Available at: http:\/\/www.lls.org\/content\/nationalcontent\/resourcecenter\/freeeducationmterial\/generalcancer\/pdf\/facts.pdf. Accessed November 14, 2014."},{"key":"10.1016\/j.clml.2015.02.025_bib2","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1177\/107327481201900305","article-title":"Diffuse large B-cell lymphoma: current strategies and future directions","volume":"19","author":"Cultrera","year":"2012","journal-title":"Cancer Control"},{"year":"2012","series-title":"Cancer Facts and Figures\u00a02012","key":"10.1016\/j.clml.2015.02.025_bib3"},{"key":"10.1016\/j.clml.2015.02.025_bib4","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V89.11.3909","article-title":"A\u00a0clinical evaluation of the International Lymphoma Study Group classification of\u00a0non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project","volume":"89","year":"1997","journal-title":"Blood"},{"year":"2009","series-title":"Hematology: Basic Principles and Practice","author":"Hoffman","key":"10.1016\/j.clml.2015.02.025_bib5"},{"key":"10.1016\/j.clml.2015.02.025_bib6","doi-asserted-by":"crossref","first-page":"3848","DOI":"10.1200\/JCO.2010.33.4474","article-title":"Watchful waiting in low-tumor burden follicular lymphoma in the rituximab era: results of an F2-study database","volume":"30","author":"Solal-C\u00e9ligny","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 3","key":"10.1016\/j.clml.2015.02.025_bib7","doi-asserted-by":"crossref","first-page":"iii76","DOI":"10.1093\/annonc\/mdu200","article-title":"Newly diagnosed and relapsed follicular lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"25","author":"Dreyling","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2015.02.025_bib8","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3960\/jslrt.54.31","article-title":"Treatment of follicular lymphoma","volume":"54","author":"Izutsu","year":"2014","journal-title":"J\u00a0Clin Exp Hematop"},{"key":"10.1016\/j.clml.2015.02.025_bib9","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/ajh.23674","article-title":"Follicular lymphoma: 2014 update on diagnosis and management","volume":"89","author":"Freedman","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2015.02.025_bib10","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1097\/CCO.0b013e328356898b","article-title":"Early stage follicular lymphoma, current management and controversies","volume":"24","author":"Jacobson","year":"2012","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.clml.2015.02.025_bib11","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1200\/JCO.1996.14.4.1282","article-title":"Is radiotherapy curative for stage I and II low grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University","volume":"14","author":"MacManus","year":"1996","journal-title":"J\u00a0Clin Oncol"},{"issue":"5 suppl 14","key":"10.1016\/j.clml.2015.02.025_bib12","first-page":"58","article-title":"Review of radiolabeled antibody therapy of B-cell lymphomas","volume":"26","author":"Press","year":"1999","journal-title":"Semin Oncol"},{"key":"10.1016\/j.clml.2015.02.025_bib13","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.beha.2011.03.005","article-title":"Radioimmunotherapy in follicular lymphoma","volume":"24","author":"Illidge","year":"2011","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.clml.2015.02.025_bib14","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1200\/JCO.2002.11.076","article-title":"Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma","volume":"20","author":"Witzig","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2015.02.025_bib15","doi-asserted-by":"crossref","first-page":"5156","DOI":"10.1200\/JCO.2008.17.2015","article-title":"Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma","volume":"26","author":"Morschhauser","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 2","key":"10.1016\/j.clml.2015.02.025_bib16","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1634\/theoncologist.2009-S2-17","article-title":"Rationale for consolidation to improve progression-free survival in patients with\u00a0non-Hodgkin's lymphoma: a review of the evidence","volume":"14","author":"Morschhauser","year":"2009","journal-title":"Oncologist"},{"key":"10.1016\/j.clml.2015.02.025_bib17","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1200\/JCO.2012.45.6400","article-title":"90Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the international, randomized, phase III first-line indolent trial","volume":"31","author":"Morschhauser","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2015.02.025_bib18","first-page":"771","article-title":"La versi\u00f3n espa\u00f1ola del SF-36 health survey (Cuestionario de Salud SF-36): un instrumento para la medida de los resultados","volume":"104","author":"Alonso","year":"1995","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.clml.2015.02.025_bib19","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1002\/pon.1405","article-title":"Quality of life in the chemotherapy treatment of Spanish cancer patients: a comparison of general population norms","volume":"18","author":"Costa-Requena","year":"2009","journal-title":"Psychooncology"},{"key":"10.1016\/j.clml.2015.02.025_bib20","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.ijom.2012.11.014","article-title":"Assessment of quality of life of oral cancer survivors compared with Spanish populations norms","volume":"42","author":"Herce-Lopez","year":"2013","journal-title":"Int J Oral Maxillofac Surg"},{"key":"10.1016\/j.clml.2015.02.025_bib21","doi-asserted-by":"crossref","first-page":"626035","DOI":"10.1155\/2012\/626035","article-title":"Exploring risk factors for follicular lymphoma","volume":"2012","author":"Ambinder","year":"2012","journal-title":"Adv Hematol"},{"key":"10.1016\/j.clml.2015.02.025_bib22","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","article-title":"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial","volume":"377","author":"Salles","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2015.02.025_bib23","first-page":"1307","article-title":"Radioimmunotherapy confers long-term survival for lymphoma patients with acceptable toxicity: registry analysis by the International Radioimmunotherapy Network","volume":"90","author":"Hohloch","year":"2011","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.clml.2015.02.025_bib24","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1007\/s12185-014-1636-5","article-title":"Factors associated with effects of (90)Y-ibritumomab tiuxetan in patients with relapsed or refractory low-grade B cell non-Hodgkin lymphoma: single-institution experience with 94 Japanese patients in rituximab era","volume":"100","author":"Uike","year":"2014","journal-title":"Int J Hematol"},{"key":"10.1016\/j.clml.2015.02.025_bib25","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1097\/PPO.0b013e31826aed4f","article-title":"Has single-agent rituximab replaced watch-and-wait for patient with asymptomatic low-grade follicular lymphoma?","volume":"18","author":"Lowry","year":"2012","journal-title":"Cancer J"},{"key":"10.1016\/j.clml.2015.02.025_bib26","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S0140-6736(03)14110-4","article-title":"Long-term effect of a watch and wait policy\u00a0versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial","volume":"362","author":"Ardeshna","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2015.02.025_bib27","doi-asserted-by":"crossref","unstructured":"Ardeshna KM, Qian W, Smith P, et\u00a0al. An intergroup randomised trial of rituximab versus a watch and wait strategy in patients with stage II, III, IV asymptomatic, non-bulky follicular lymphoma (grades 1, 2 and 3a): a preliminary analysis. Paper presented at: 53rd ASH Annual Meeting and Exposition; December 10-13, 2011; San Diego, CA; abstract 6, plenary session. Available at: https:\/\/ash.confex.com\/ash\/2010\/webprogram\/Paper27692.html. Accessed November 14, 2014.","DOI":"10.1182\/blood.V116.21.6.6"},{"key":"10.1016\/j.clml.2015.02.025_bib28","first-page":"41274","article-title":"RIT with Y90-ibritumomab tiuxetan in follicular non-Hodgkin lymphoma: evaluation of recent outcomes in a single institution","volume":"2012","author":"Andrade Campos","year":"2012","journal-title":"J\u00a0Oncol"},{"key":"10.1016\/j.clml.2015.02.025_bib29","doi-asserted-by":"crossref","first-page":"896","DOI":"10.2967\/jnumed.111.087460","article-title":"Six of 12 relapsed refractory indolent lymphoma patients treated 10 years ago with 131-I-tositumomab remain in complete remission","volume":"52","author":"Buchegger","year":"2011","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.clml.2015.02.025_bib30","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.3324\/haematol.2013.088377","volume":"98","author":"Arranz","year":"2013","journal-title":"Haematologica"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265015000695?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265015000695?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:26:40Z","timestamp":1761870400000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265015000695"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["S2152265015000695"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2015.02.025","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2015,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patients Older Than 65 Years With Non-Hodgkin Lymphoma Are Suitable for Treatment With 90Yttrium-Ibritumumab Tiuxetan: A Single-Institution Experience","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2015.02.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}